Back grey_arrow_rt.gif
 
Archived NATAP Articles from October 2003
 
null.gif
 
 
  1. High Dose Peginterferon for Non-responders, and Naïve & Relapsers - (10/31/03)
     
  2. DRUG USE COMMON IN YOUNG MEN WITH MALE SEX PARTNERS - (10/30/03)
     
  3. Many Teenage Girls Underestimate STD Risk: Study - (10/30/03)
     
  4. PROGRESSION AND TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION IN PATIENTS CO-INFECTED WITH HIV. - (10/30/03)
     
  5. EFFICACY AND TOLERABILITY OF PREEMPTIVE INTERFERON (IFN) VERSUS IFN PLUS RIBAVIRIN (RBV) TREATMENT IN HEPATITIS C VIRUS (HCV) INFECTED LIVER TRANSPLANT RECIPIENTS - (10/30/03)
     
  6. HCV Vaccines: early research - (10/30/03)
     
  7. The Immune Response to HCV: implications for HCV/HIV co-infection - (10/30/03)
     
  8. BILN 2061: HCV protease inhibitor - (10/30/03)
     
  9. SCHERING-PLOUGH REPORTS NOVEL INVESTIGATIONAL PROTEASE INHIBITOR SHOWS IN VITRO ANTIVIRAL ACTIVITY IN HEPATITIS C INFECTION - (10/29/03)
     
  10. Early Viral Kinetics Prediction of Sustained Viral Response After 1 or 4 Weeks of Peg-Interferon-a-2a (40KD) and Ribavirin Therapy (DITTO-HCV Project) - (10/29/03)
     
  11. FIBROSIS PROGRESSION IN 914 HIV-HCV CO-INFECTED PATIENTS IS STRONGLY RELATED WITH AGE: EUROPEAN COLLABORATIVE STUDY - (10/29/03)
     
  12. Fatty Liver, Liver Disease and Weight Loss - (10/28/03)
     
  13. Press Release from Vertex Pharmaceuticals - (10/28/03)
     
  14. Hepatitis C: new antiviral developments - (10/28/03)
     
  15. Pegasys plus Ribavirin (Copegus) for African-Americans with Hepatitis C Genotype 1 - (10/27/03)
     
  16. Sexual Transmission of Hepatitis C Virus in Heterosexual Monogomous Couples - The HCV Partners Study - (10/27/03)
     
  17. Pegasys/Ribavirin in African Americans Showed Improved or Stabilized Fibrosis in Nonresponders - (10/27/03)
     
  18. Natural History of Fibrosis in Chronic Hepatitis C - (10/27/03)
     
  19. Intrafamilial Transmission of Hepatitis C Virus in Patients with Acute Hepatitis C: correlation with virologic and immunologic parameters - (10/27/03)
     
  20. COMPARING THE PUBLIC HEALTH BURDEN OF CHRONIC HEPATITIS C AND HIV INFECTION IN UNITED STATES - (10/27/03)
     
  21. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C - (10/24/03)
     
  22. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine - (10/24/03)
     
  23. Sexual transmission of hepatitis C and early intervention - (10/24/03)
     
  24. Iron depletion and response to interferon in chronic hepatitis C - (10/24/03)
     
  25. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse - (10/24/03)
     
  26. Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? - (10/24/03)
     
  27. Cardiac surgery in patients infected with the human immunodeficiency virus - (10/24/03)
     
  28. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function - (10/24/03)
     
  29. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy - (10/23/03)
     
  30. FDA Approves LEXIVA (fosamprenavir): study results for teatment naive & experienced, safety, adverse events, contrindications, drug interactions, pharmacology, and more - (10/23/03)
     
  31. Vertex Reports Six-Month Results from Phase II Clinical Study of Merimepodib (VX-497) in HCV - (10/17/03)
     
  32. TMC-114, new protease inhibitor for PI resistance - (10/16/03)
     
  33. New NYC Co-infection Clinic: AIDS Center at Montefiore Hospital in Bronx, New York Initiates Hepatitis C Program - (10/16/03)
     
  34. High Viral Failure Rate for ddI+3TC+Tenofovir: FDA Announces Dear Doctor Letter from Gilead Sciences - (10/15/03)
     
  35. Brief Report: Gender Differences in Antiretroviral Drug-Related Adipose Tissue Alterations: Women Are at Higher Risk Than Men and Develop Particular Lipodystrophy Patterns - (10/15/03)
     
  36. Factors Associated With Mitochondrial Dysfunction in Circulating Peripheral Blood Lymphocytes From HIV-Infected People - (10/15/03)
     
  37. HCV Infections in Newly Freed Inmates Are a Rising Concern - (10/15/03)
     
  38. HMO Approves Kidney Transplant for HIV Patient - (10/15/03)
     
  39. FDA Announcement, Oct 2003 Norvir Package Insert Changes - (10/10/03)
     
  40. New Drug for For Liver Transplantation - (10/9/03)
     
  41. Immunology: Biologist Finds HIV Gene Makes a Human Gene Turn Bad - (10/9/03)
     
  42. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment - (10/9/03)
     
  43. Structured interruptions of therapy: looking for the best protocol - (10/9/03)
     
  44. HIV transmission among gay men through oral sex and other uncommon routes: case series of HIV seroconverters, Sydney - (10/9/03)
     
  45. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals - (10/8/03)
     
  46. Treating hepatitis C in methadone maintenance patients: an interim analysis - (10/8/03)
     
  47. The Nation's HIV Providers Speak Out to Help Save ADAP - (10/8/03)
     
  48. Role of Structured Treatment Interruption before a 5-Drug Salvage Antiretroviral Regimen: The Retrogene Study - (10/7/03)
     
  49. Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor - (10/7/03)
     
  50. ICAAC - Anti-Hepatitis B Virus (HBV) Activity of Tenofovir Disoproxil Fumarate (TDF) in Human Immunodeficiency Virus (HIV) Co-Infected Patients - (10/6/03)
     
  51. Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort - (10/6/03)
     
  52. Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) - (10/6/03)
     
  53. Management of chronic hepatitis B - (10/2/03)